Navigation Links
Unigene and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127
Date:11/27/2012

ficer of Tarix, commented, "TXA127 has always been a high-value opportunity, given its potential to treat multiple therapeutic conditions. However, our ability to potentially deliver TXA127 orally will significantly enhance its transactability with prospective advanced-stage development partners and serves to greatly differentiate it from other peptide-based drugs. Based on our experience, Unigene's Peptelligence™ technology and feasibility program offer the potential to truly transform the therapeutic peptide market."

In September, data from a feasibility study of TXA127 demonstrated that the oral formulation produced extremely high exposure in the blood that resulted in a several-fold increase in bioavailability as compared to the oral delivery of the unformulated drug, and was equal to or greater than that achieved by the current subcutaneous formulation.

About TXA127
TXA127 is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7).  Tarix is developing TXA127 for multiple therapeutic indications, including enhancement of engraftment following peripheral blood and cord blood stem cell transplantation, stroke recovery, peripheral vascular disease and diabetes. TXA127 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) as a treatment for pulmonary arterial hypertension, to enhance engraftment in patients receiving a stem cell transplant, and for Myelodysplastic Syndrome (MDS). Tarix is developing a related peptide, PanCyte, for stroke and diabetes.

About Tarix Pharmaceuticals
Tarix Pharmaceuticals is a clinical stage biopharmaceutical company developing peptide drugs to address significant unmet medical needs. The Company's lead product, TXA127, is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). TXA127 is currently in a Phase II clinical trial for peripheral blood stem cell engraftment, and in earlier-stage trials for cord blood tr
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Unigene to Announce Third Quarter 2012 Financial Results on November 20, 2012
2. Unigene To Present at the 2012 Obesity Societys 30th Annual Scientific Meeting
3. Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-engineered" TXA127
4. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
5. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
6. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
7. Unigene to Present at TIDES 2012
8. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
9. Edison Pharmaceuticals Closes $20M Series F Financing
10. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
11. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ... biology, human genetics, genomic technology, and drug discovery ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014 /PRNewswire/ ... "Lifetime in Dermatology Achievement Award" from the Journal ... Orlando Dermatology Aesthetic & Clinical Conference (ODAC). The event ... in Florida . ... comprehensive report on the practice of dermatology for clinical ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of ... able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Device Industry, it steadfastly remains one of ... involving IP infringement. This litigious nature can ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... Inc. magazine has ranked Universal SmartComp #503 ... fourth annual Inc. 5000, an exclusive ranking of the ... comprehensive look at the most important segment of the ... 7-Eleven, Brooklyn Brewery, and Radio Flyer, maker of the ...
... SILVER SPRING, Md., Sept. 24 The U.S. ... an estrogen/progestin combined oral contraceptive that also contains ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: ... a metabolite of folic acid, a water-soluble B-vitamin ...
Cached Medicine Technology:Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 2Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 3FDA Approves Combination Contraceptive Containing a Folate 2
(Date:4/15/2014)... States have nearly doubled since 1988, suggests new research ... with obesity apparently to blame for the surge. The ... has not hit all groups equally, with alarming increases ... According to new research reported in the April 15, ... , diabetes increased from 6 percent to 10 percent ...
(Date:4/15/2014)... have solved a decades-old medical mystery and in the ... invasive fungal infections, which kill about 1.5 million people a ... action of amphotericin, an antifungal drug that has been in ... is nearly as toxic to human cells as it is ... of the new findings appears in Nature Chemical Biology ...
(Date:4/15/2014)... School of Medicine have identified a mechanism that explains ... disease and why the virus is able to persist ... hard-to-kill pathogen, which infects an estimated 200 million people ... mitochondria dismantling the cell,s innate ability to fight ... , The study, published in today,s issue of the ...
(Date:4/14/2014)... children orphaned by HIV/AIDS in South Africa may provide ... emotional behavior issues in other areas of the world, ... research that could lead to successful interventions. , ... the United Nations mentions that due to the HIV/AIDS ... Sub-Saharan African, children are at an increased risk for ...
(Date:4/14/2014)... Va., USA The International and American Associations ... titled "Rare Bone Diseases and Their Dental, Oral, ... Sunday O. Akintoye, Andrea B. Burke, Alison M. ... Gafni, Janice S. Lee, Mary Scott Ramnitz, Martha ... in the OnlineFirst portion of the IADR/AADR ...
Breaking Medicine News(10 mins):Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2
... Practice Arm of the School,s Department of Forensic ... Jan. 30 The Chicago School of ... its psychology services to the legal sector and ... thanks to its new Forensic Center, which was ...
... Kroger Co. (NYSE: KR ),said today it is ... stores,because the product was associated with peanut butter supplied by ... Stores under the following names in ... Kroger, Ralphs, Fred Meyer, Food 4 Less, Fry,s,King Soopers, ...
... grid of small arteries at the surface of the brain ... supply to tissue starved of nutrients and oxygen following a ... is optimistic news," said David Kleinfeld, a physics professor at ... flow in animal models of stroke. , Damage from stroke ...
... ) AMDL, Inc. (NYSE Alternext US: ADL), a vertically ... the US, announced today the second and final closing ... notes and warrants. The exclusive placement agent for ... on December 8, 2008, AMDL sold $1,077,500 of 12% ...
... school shootings, other tragedies , , FRIDAY, Jan. 30 (HealthDay ... people into hotheads. , A University of Kentucky study ... likely to view other people,s actions as hostile and ... , The researchers said their findings may help explain ...
... up bad lipoproteins, researchers say , , FRIDAY, Jan. ... (HDL) -- the "good" cholesterol -- may hold ... the deadly cardiovascular disease it can cause. , ... is close in size to natural HDL with ...
Cached Medicine News:Health News:New Chicago School of Professional Psychology Forensic Center Opens Doors to the Community 2Health News:New Chicago School of Professional Psychology Forensic Center Opens Doors to the Community 3Health News:Kroger Recalls Nut Topping Due to Possible Health Risk 2Health News:Mesh-like network of arteries adjusts to restore blood flow to stroke-injured brain 2Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 2Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 3Health News:Those Who Feel Rejected Direct Hostility Toward Others 2Health News:Synthetic HDL Could Fight Heart Disease 2
... Detection Reagents provide molecular labs a more ... By using our MGB technology, combined with ... now able to provide molecular labs more ... of specific organisms or genetic mutations associated ...
... MGB Alert Detection Reagents provide molecular labs ... based assays. By using our MGB technology, ... Nanogen is now able to provide molecular ... acid sequences of specific organisms or genetic ...
... and most advanced fecal occult blood test ... immunochemical FOBT (iFOBT) with high specificity and ... detect bleeding associated with more cancers and ... its superior specificity for lower GI bleeding, ...
... Capture vital signs faster, easier, ... Signs LXi, the latest innovation in ... With Spot LXi, you get more ... the flexibility to customize it to ...
Medicine Products: